Case todayOn watchEarly warning: revenue decline (trailing 12 months) · Nov 17, 2026The case · mixed · Nov 17, 2026Own IMDX if IMDX is a high-risk option on molecular transplant-rejection testing becoming a payer-covered, recurring diagnostics business before the balance sheet forces value-destructive financing.5 conditions1 strengthening · 1 holding · 3 weakeningNext resultsFeb 15, 2027Projected from its filing dates

IMDX at a glance

The past year

Chart

−76.6% $1.57, close Nov 18

From the highest close
−79.1%
Vs the 200-day average
−64.8%
Nov 17, 2025Daily close, Insight Molecular DiagnosticsNov 18, 2026

Short interest

History

1.0M shares

Of shares outstanding
3.13%
Since the last report
+8.0%
Days to cover
5.1 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 13 – Nov 19

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

IMDX price history

Latest price$1.78Today+$0.19 (+11.95%)
IMDX -38.19%S&P 500 -5.21%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand.HoldingMateriality: High

    GAAP annual revenue increased from $0.958 million in FY2022 to $4.055 million in FY2025. If adoption holds, the company has a path from niche diagnostic capability to repeat testing revenue; if adoption fails, the revenue base is too small to support the company.

    Watch: Transplant programs standardize on established competing molecular tests from CareDx or Natera instead of adopting IMDX’s offering.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue increased from $0.958 million in FY2022 to $4.055 million in FY2025.

    Open source ↗
  • The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service.StrengtheningMateriality: High

    GAAP annual gross profit improved from negative $0.018 million in FY2022 to $2.298 million in FY2025. Gross economics determine whether incremental adoption can eventually fund commercialization instead of simply adding unprofitable volume.

    Watch: Medicare or commercial payers reduce reimbursement rates, impose prior authorization, or deny coverage for the relevant tests.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual gross profit improved from negative $0.018 million in FY2022 to $2.298 million in FY2025.

    Open source ↗
  • IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization.WeakeningMateriality: Medium

    Cash was $11.583 million at FY2025 year-end. Even a valid clinical product can be a poor equity outcome if the company runs out of runway before adoption reaches scale.

    Watch: Capital markets remain closed to small, loss-making diagnostics companies, forcing highly dilutive equity issuance.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $11.583 million at FY2025 year-end.

    Open source ↗
  • Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale.WeakeningMateriality: Medium

    GAAP annual operating loss improved from negative $61.041 million in FY2024 to negative $51.124 million in FY2025. If fixed costs fall or revenue scales without proportional spending, equity value can accrue; if not, growth will continue to consume cash.

    Watch: IMDX must build a larger direct sales force, medical-affairs team, or billing infrastructure before transplant-test volume materializes.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating loss improved from negative $61.041 million in FY2024 to negative $51.124 million in FY2025.

    Open source ↗
  • The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics.WeakeningMateriality: Medium

    Stockholders’ equity declined from positive $20.468 million at FY2023 year-end to negative $31.464 million at FY2025 year-end. For the stock, not just the product, to work, balance-sheet claims and dilution cannot absorb the value created by future test adoption.

    Watch: Debt holders, preferred investors, or warrant holders receive terms that capture most of the upside from future commercialization.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders’ equity declined from positive $20.468 million at FY2023 year-end to negative $31.464 million at FY2025 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand. If adoption holds, the company has a path from niche diagnostic capability to repeat testing revenue; if adoption fails, the revenue base is too small to support the company.

The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service. Gross economics determine whether incremental adoption can eventually fund commercialization instead of simply adding unprofitable volume.

IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization. Even a valid clinical product can be a poor equity outcome if the company runs out of runway before adoption reaches scale.

Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale. If fixed costs fall or revenue scales without proportional spending, equity value can accrue; if not, growth will continue to consume cash.

The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics. For the stock, not just the product, to work, balance-sheet claims and dilution cannot absorb the value created by future test adoption.

All standing thesis claims
Original report summary

IMDX is a high-risk option on molecular transplant-rejection testing becoming a payer-covered, recurring diagnostics business before the balance sheet forces value-destructive financing.

Evidence assessed Nov 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Insight Molecular Diagnostics

Where the evidence on Insight Molecular Diagnostics disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 5 thesis points, 1 strengthening, 1 holding and 3 weakening.

Bull case: what the evidence supports

  • Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand.

    sec.gov ↗

  • The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service.

    sec.gov ↗

Bear case: what the evidence questions

  • IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization.

    sec.gov ↗

  • Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale.

    sec.gov ↗

  • The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Insight Molecular Diagnostics

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Insight Molecular Diagnostics’s thesis. Its break conditions are checked against every new filing as it lands.

Early warning

The break condition read on the trailing twelve months through Insight Molecular Diagnostics’s latest quarterly report, ahead of the annual figure it is written on.

  • Revenue decline, trailing 12 months

    Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat the market by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Insight Molecular Diagnostics filed an SEC 8-K on 2026-11-16: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Insight Molecular Diagnostics filed an SEC 8-K on 2026-09-21: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Insight Molecular Diagnostics filed an SEC 8-K on 2026-08-10: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Transplant programs standardize on established competing molecular tests from CareDx or Natera instead of adopting IMDX’s offering.
  • Medicare or commercial payers reduce reimbursement rates, impose prior authorization, or deny coverage for the relevant tests.
  • Capital markets remain closed to small, loss-making diagnostics companies, forcing highly dilutive equity issuance.
  • IMDX must build a larger direct sales force, medical-affairs team, or billing infrastructure before transplant-test volume materializes.
  • Debt holders, preferred investors, or warrant holders receive terms that capture most of the upside from future commercialization.

IMDX news

Loading headlines…

Financial statements

IMDX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

IMDX: quick answers

When does Insight Molecular Diagnostics (IMDX) report earnings next?
Insight Molecular Diagnostics's next results are projected for February 15, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 16, 2026. Earnings calendar
What is IMDX's short interest?
As of October 30, 2026, 1.0M IMDX shares were sold short, 3.13% of its shares outstanding, up 8.0% from the count before. At the stock's average daily volume that is 5.1 days to cover. FINRA publishes the count twice a month. IMDX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.